Dermatology Times

DECEMBER 11, 2024

Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.

Innovations 69

Innovations Therapy Clinic 69

Beauty Launchpad

DECEMBER 11, 2024

Attitudes towards charging a Green Fee are being assessed this month in a new study organized by Sustain Beauty Co.

Sustainability 52

Sustainability 52

Skin Inc

DECEMBER 11, 2024

Master Chemist Sam Dhatt On Innovative Ingredients In The Skin Care Industry, Perfecting His Formulations And Efficacy Of Products

Innovations 52

Innovations Ingredients 52

The Dermatology Digest

DECEMBER 11, 2024

SYM2081 inhibits inflammation-driving mast cells in mouse models and human skin samples, paving the way for new topical treatments to prevent itching, hives, and other symptoms of skin conditions driven by mast cells, finds a study published in Science Translational Medicine. Im really excited about the clinical possibilities of this research, says senior author Daniel Kaplan, MD, PhD, Professor of Dermatology and Immunology at the University of Pittsburgh in Pittsburgh, PA, in a news release.

Therapy 41

Therapy Rosacea Entrepreneurship Eczema 41

Dermatology Times

DECEMBER 11, 2024

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

Treatments 41

Treatments 41

Spa Industry Association

DECEMBER 11, 2024

Allan experiences and shares his thoughts on OptiStrips. Silicone strips for comfortable glasses wear. Continue reading OptiStrips…adding comfort to wearing glasses at Spa Industry Association.

40

40

The Dermatology Digest

DECEMBER 11, 2024

The U.S. Food and Drug Administration (FDA) has cleared Astria Therapeutics Investigational New Drug (IND) application to study STAR-0310 in atopic dermatitis (AD). STAR-0310 is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. A Phase 1a trial of STAR-0310 in healthy subjects is expected to initiate in the first quarter of 2025, with early proof-of-concept results expected in the third quarter of 2025.

Dermatitis 36

Dermatitis Office Dermatology Medical 36

Dermatology Times

DECEMBER 11, 2024

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

Treatments 36

Treatments 36

The Dermatology Digest

DECEMBER 11, 2024

Veradermics closed a $75 million Series B financing which will be used to fund the ongoing pivotal clinical development of VDPHL01 for the treatment of androgenetic alopecia (AGA). VDPHL01 is a non-hormonal oral therapeutic. The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA. The trial will enroll approximately 480 patients across 44 sites in the United States.

Office 36

Office Innovations Management Clinic 36

Dermatology Times

DECEMBER 11, 2024

Although further trials are needed, this multidimensional, minimally invasive approach showed positive results in 4 patients.

28

28

The Dermatology Digest

DECEMBER 11, 2024

AnaptysBio, Inc.is pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The drug was being studied as a monotherapy for moderate-to-severe AD in the global, 201-patient ARISE-AD trial. Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported.

Safety 36

Safety Dermatitis Therapy Dermatology 36

Rosy Salon Software

DECEMBER 11, 2024

It’s been said that hairdressers are like therapists. For those of us who’ve tirelessly worked behind the chair doing hair while clients unload about their day, latest love or heartbreak, greatest achievement or recent failure, we know – to a very large degree – it’s true.

Salon 52

Salon 52